TOP TEN perturbations for 39995_s_at (Homo sapiens)

Organism: Homo sapiens
Gene: 39995_s_at
Selected probe(set): 219077_s_at
Platform: Affymetrix Human Genome U133 Plus 2.0 Array

Expression of 39995_s_at (219077_s_at) across 6674 perturbations tested by GENEVESTIGATOR:

lung cancer study 1 (PDX; non-small cell carcinoma; primary) / lung cancer study 1 (PDX; basaloid carcinoma; primary)

Relative Expression (log2-ratio):-4.595752
Number of Samples:2 / 3
Experimental lung cancer study 1 (PDX; non-small cell carcinoma; primary)
Patient-derived xenograft (PDX) samples generated in female athymic nude mice from patients with primary non-small cell carcinoma of the lung (subcutaneously implanted).
Control lung cancer study 1 (PDX; basaloid carcinoma; primary)
Patient-derived xenograft (PDX) samples generated in female athymic nude mice from patients with primary basaloid carcinoma of the lung (subcutaneously implanted).

bone cancer study 1 (PDX; chondrosarcoma, NOS; primary) / bone cancer study 1 (PDX; osteosarcoma, NOS; primary)

Relative Expression (log2-ratio):-4.1604204
Number of Samples:2 / 2
Experimental bone cancer study 1 (PDX; chondrosarcoma, NOS; primary)
Patient-derived xenograft (PDX) samples generated in female athymic nude mice from patients with primary chondrosarcoma, NOS of the bone (subcutaneously implanted).
Control bone cancer study 1 (PDX; osteosarcoma, NOS; primary)
Patient-derived xenograft (PDX) samples generated in female athymic nude mice from patients with primary osteosarcoma, NOS of the bone (subcutaneously implanted).

bone cancer study 1 (PDX; chondrosarcoma, NOS; primary) / bone cancer study 1 (PDX; chondroblastic osteosarcoma; primary)

Relative Expression (log2-ratio):-4.1045933
Number of Samples:2 / 2
Experimental bone cancer study 1 (PDX; chondrosarcoma, NOS; primary)
Patient-derived xenograft (PDX) samples generated in female athymic nude mice from patients with primary chondrosarcoma, NOS of the bone (subcutaneously implanted).
Control bone cancer study 1 (PDX; chondroblastic osteosarcoma; primary)
Patient-derived xenograft (PDX) samples generated in female athymic nude mice from patients with primary chondroblastic osteosarcoma of the bone (subcutaneously implanted).

cisplatin study 4 (20uM) / vehicle (PBS) treated HepG2 sample

Relative Expression (log2-ratio):-3.761496
Number of Samples:3 / 12
Experimental cisplatin study 4 (20uM)
HepG2 cells treated with compound: cisplatin (20uM; CAS no.:15663-27-1) for 24 hours. Cisplatin is hepatotoxic and may cause necrosis. HepG2 cells were treated with the IC20 concentration measured after 72 hours. ATC code:
Control vehicle (PBS) treated HepG2 sample
HepG2 cells treated with PBS (0.5% v/v) as solvent control for 24 hours.

ovarian tumor study 30 (PDX; clear cell adenocarcinoma, NOS; primary) / ovarian tumor study 30 (PDX; adenocarcinoma, NOS; primary)

Relative Expression (log2-ratio):3.758604
Number of Samples:2 / 2
Experimental ovarian tumor study 30 (PDX; clear cell adenocarcinoma, NOS; primary)
Patient-derived xenograft (PDX) samples generated in female athymic nude mice from patients with primary clear cell adenocarcinoma, NOS of the ovary (subcutaneously implanted).
Control ovarian tumor study 30 (PDX; adenocarcinoma, NOS; primary)
Patient-derived xenograft (PDX) samples generated in female athymic nude mice from patients with primary adenocarcinoma, NOS of the ovary (subcutaneously implanted).

cyclophosphamide study 6 (8155 uM; hES-Heps) / vehicle (DMSO) treated hES-Heps cell sample

Relative Expression (log2-ratio):-3.7332325
Number of Samples:3 / 8
Experimental cyclophosphamide study 6 (8155 uM; hES-Heps)
hES-Heps cells exposed to 8155 uM cyclophosphamide (dissolved in 0.5% v/v DMSO) for 72 hours. Chemical was added at day 22 of differentiation. Cells were treated with the IC10 determined by a 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide test (number of replicates, n = 3). ATC code:
Control vehicle (DMSO) treated hES-Heps cell sample
hES-Heps cells treated with vehicle (DMSO 0.5% v/v) for 72 hours. Vehicle was added at day 22 of differentiation.

cisplatin study 7 (48h) / vehicle (PBS) treated HepG2 cell sample

Relative Expression (log2-ratio):-3.706049
Number of Samples:3 / 9
Experimental cisplatin study 7 (48h)
HepG2 cells exposed to 20μM cisplatin in PBS solvent for 48 hours. ATC code:
Control vehicle (PBS) treated HepG2 cell sample
HepG2 cells exposed to 0.5% PBS solvent for 48 hours.

polyamide study 1 (match) / mifepristone study 4

Relative Expression (log2-ratio):-3.6913986
Number of Samples:3 / 3
Experimental polyamide study 1 (match)
Human non-small cell bronchoepithelial carcinoma cell line A549 grown in F12-K medium supplemented with 10% FBS and 4mM penicillin and streptomycin. After 24 hours the medium was replaced with F12-K containing 10% CT-FBS, 4mM penicillin/streptomycin and a synthetic DNA-binding polyamide (targeting the consensus sequence of the glucocorticoid receptor element and binding the glucocorticoid-induced zipper GILZ). After 48 hours 10nM dexamethasone was added to the cell culture. Samples were taken after additional 6 hours.
Control mifepristone study 4
Human non-small cell bronchoepithelial carcinoma cell line A549 grown in F12-K medium supplemented with 10% FBS and 4mM penicillin and streptomycin. After 24 hours the medium was replaced with F12-K containing 10% CT-FBS, 4mM penicillin/streptomycin and 3µM of the glucocorticoid receptor antagonist mifepristone. After 48 hours 10nM dexamethasone was added to the cell culture. Samples were taken after additional 6 hours. ATC code:

polyamide study 1 (mismatch) / mifepristone study 4

Relative Expression (log2-ratio):-3.6214275
Number of Samples:3 / 3
Experimental polyamide study 1 (mismatch)
Human non-small cell bronchoepithelial carcinoma cell line A549 grown in F12-K medium supplemented with 10% FBS and 4mM penicillin and streptomycin. After 24 hours the medium was replaced with F12-K containing 10% CT-FBS, 4mM penicillin/streptomycin and a mismatched synthetic DNA-binding polyamide (normally targeting the consensus sequence of the glucocorticoid receptor element and binding the glucocorticoid-induced zipper GILZ). After 48 hours 10nM dexamethasone was added to the cell culture. Samples were taken after additional 6 hours.
Control mifepristone study 4
Human non-small cell bronchoepithelial carcinoma cell line A549 grown in F12-K medium supplemented with 10% FBS and 4mM penicillin and streptomycin. After 24 hours the medium was replaced with F12-K containing 10% CT-FBS, 4mM penicillin/streptomycin and 3µM of the glucocorticoid receptor antagonist mifepristone. After 48 hours 10nM dexamethasone was added to the cell culture. Samples were taken after additional 6 hours. ATC code:

polyamide study 1 (match) / vehicle (medium) treated A549 cell sample

Relative Expression (log2-ratio):-3.594263
Number of Samples:3 / 3
Experimental polyamide study 1 (match)
Human non-small cell bronchoepithelial carcinoma cell line A549 grown in F12-K medium supplemented with 10% FBS and 4mM penicillin and streptomycin. After 24 hours the medium was replaced with F12-K containing 10% CT-FBS, 4mM penicillin/streptomycin and a synthetic DNA-binding polyamide (targeting the consensus sequence of the glucocorticoid receptor element and binding the glucocorticoid-induced zipper GILZ). After 48 hours 10nM dexamethasone was added to the cell culture. Samples were taken after additional 6 hours.
Control vehicle (medium) treated A549 cell sample
Human non-small cell bronchoepithelial carcinoma cell line A549 grown in F12-K medium supplemented with 10% FBS and 4mM penicillin and streptomycin. After 24 hours the medium was replaced with F12-K containing 10% CT-FBS and 4mM penicillin/streptomycin. Samples were taken after additional 56 hours.